A strong genetic association of a microglial molecule with AD, for example, CD33, complement receptor 1 (CR1), phospholipase C gamma 2 (PLCγ2), and TREM2 (Wes et al., 2016; Henstridge et al., 2019), also suggests promise as a drug target. This evidence concerns the gene TREM2 and Alzheimer disease.